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ABSTRACT
Purpose: The robotic system for surgery was introduced to gastric cancer surgery in the early 
2000s to overcome the shortcomings of laparoscopic surgery. The more recently introduced 
da Vinci Xi® system offers benefits allowing four-quadrant access, greater range of motion, 
and easier docking through an overhead boom rotation with laser targeting. We aimed to 
identify whether the Xi® system provides actual advantages over the Si® system in gastrectomy 
for gastric cancer by comparing the operative outcomes.
Materials and Methods: We retrospectively reviewed all patients who underwent robotic 
gastrectomy as treatment for gastric cancer from March 2016 to March 2017. Patients' 
demographic data, perioperative information, and operative and pathological outcomes were 
collected and analyzed.
Results: A total of 109 patients were included in the Xi® group and 179 in the Si® group. 
Demographic characteristics were similar in both groups. The mean operative time was 229.9 
minutes in the Xi® group and 223.7 minutes in the Si® group. The mean estimated blood loss 
was 72.7 mL in the Xi® group and 62.1 mL in the Si® group. No patient in the Xi® group was 
converted to open or laparoscopy, while 3 patients in the Si® group were converted, 2 to open 
surgery and 1 to laparoscopy, this difference was not statistically significant. Bowel function 
was resumed 3 days after surgery, while soft diet was initiated 4 days after surgery.
Conclusions: We found no difference in surgical outcomes after robotic gastrectomy for 
gastric cancer between the da Vinci Xi® and da Vinci Si® procedures.
Keywords: Robot; Gastrectomy; Gastric cancer
INTRODUCTION
Since the introduction of robotic systems, the minimally invasive approach was further 
revolutionized. Robotic application facilitates technically challenging procedures, such as 
suturing, to be performed easily and in comfort [1,2]. Robotic gastrectomy has also been 
increasingly performed and has demonstrated satisfactory initial surgical outcomes, which 
are comparable to the laparoscopic approach [3-6].
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The da Vinci Xi® system (Intuitive Surgical, Sunnyvale, CA, USA), a new generation robotic 
surgery system, was introduced to overcome the limitations of the previous platform, the da 
Vinci Si® system. It offers better anatomical access for multi-quadrant surgical procedures 
because of the overhead boom rotation without axis limitation with a laser precision 
targeting that allows optimum boom positioning [7]. Moreover, it is equipped with an 8-mm 
endoscope that does not require draping, autofocuses and white balances, and can be used 
through all arms [8]. In addition, the da Vinci Xi® system has narrower arms and a longer 
instrument shaft, which gives the surgeon a better reach [9].
Whether these benefits influence outcomes after gastrectomy need to be investigated 
to justify the higher cost of the da Vinci Xi® system, although a few comparative studies 
comparing the da Vinci Xi® and da Vinci Si® systems when performing rectal and prostate 
surgery have been reported [1,7,9-13]. Our study aimed to evaluate the clinical efficiency of 
the da Vinci Xi® system by comparing operative outcomes in robotic gastrectomy using the da 
Vinci Xi® and da Vinci Si® systems.
MATERIALS AND METHODS
Patients
We started using the da Vinci Xi® system in March 2016. We identified 286 patients who 
underwent robotic gastrectomy from March 2016 to March 2017, 107 patients with da Vinci 
Xi® system (Xi® group) and 179 with da Vinci Si® system (Si® group). Data were acquired from 
the prospective database of gastric cancer in our institute. We obtained data regarding the 
patients' preoperative status, operative outcomes, pathological features, and immediate 
postoperative recovery results. The diagnosis of gastric adenocarcinoma was confirmed by 
preoperative endoscopy and biopsy. Abdominopelvic computed tomography was performed 
for all patients for clinical staging. Patients who were found eligible for the procedure 
provided written informed consent after the surgical approaches, costs, and risks associated 
with the surgery were clearly explained to them. Postoperative complications were graded 
using the Clavien-Dindo classification of surgical complications [14]. We classified fever, 
urinary retention, and wound complications as grade I complications. Fever was defined as 
temperature of 38.0°C or higher or the use of antipyretics, regardless of the temperature. 
Pancreatitis, pleural effusion, and transfusion were classified as grade II complications. 
Grade III complications were defined as complications requiring surgical, endoscopic, or 
radiological procedures, such as anastomosis site leakage, pulmonary thromboembolism, 
pleural effusion, and atrial fibrillation. Grade IV complications were defined as life-
threatening complications, which in our study population were new-onset left bundle branch 
block and anastomosis leakage due to a peripancreatic abscess. Grade V complication was 
patient death [14]. This retrospective study was approved by the Institutional Review Board 
(IRB) of Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea 
(IRB No. 4-2018-0048).
Surgical procedure
Our robotic gastrectomy procedures, both conventional and reduced port procedures, have 
been described previously [5,6,15-21]. Three surgeons with experience in robotic gastrectomy 
performed all the operations included in our study. These 3 surgeons performed 839, 268, 
and 12 robotic gastrectomy procedures using da Vinci Si®. The gastrectomy procedures using 
the da Vinci Xi® and da Vinci Si® systems were performed using the same approach. The Xi® 
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robotic gastrectomy procedures have been performed with the same port placement, with the 
exception of using an 8-mm port for the camera and using the laser targeting feature prior 
to docking. Conventional robotic gastrectomy was defined as a robotic gastrectomy with 5 
ports, namely, a camera port and 4 ports for robotic instruments and assistant port [5,6]. 
Reduced port surgery was defined as robotic gastrectomy using the Single-Site™ system with 
1 or 2 additional ports [15,17]. Anastomosis was performed intracorporeally in all patients.
Statistical analysis
IBM SPSS (version 23 for Mac; IBM Corp., Armonk, NY, USA) software package was used 
to perform the statistical analyses. Continuous variables were analyzed with independent 
sample t-tests and were expressed as the mean±standard deviation, while categorical 
variables were compared using χ2 tests. A P-value of <0.05 was considered significant.
RESULTS
Patients' demographic characteristics are shown in Table 1. Both groups had equal age 
distributions; age and preoperative body mass index were similar as well as past medical and 
surgical histories.
Resection extent was similar in both groups, with over 70% of patients undergoing distal 
gastrectomy, as shown in Table 2. Operative variables were not statistically different between 
the groups in terms of total operation time, docking, and console time. Total operation time 
was 196 minutes in the Xi® group and 192 minutes in the Si® group. The mean docking time 
was 4.8 minutes in the Xi® group and 4.5 minutes in the Si® group. In addition, the console 
time was 121.4 minutes in the Xi® group and 116.0 minutes in the Si® group.
The conversion rate was not statistically different, although there were 3 conversions in the 
Si® group and none in the Xi® group. Of the 3 converted patients in the Si® group, 2 converted 
to open surgery because of severe adhesions in 1 patient and gastrocolic vein bleeding in the 
other, and 1 converted to laparoscopic secondary due to a trocar-related mechanical problem.
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Table 1. Patients' demographic data
Variables All (n=286) Conventional (n=169) Reduced port (n=117)
Xi® (n=107) Si® (n=179) P-value Xi® (n=61) Si® (n=108) P-value Xi® (n=46) Si® (n=71) P-value
Age (yr) 55.8±13.7 56.8±11.8 0.509 57.6±14.6 57.6±11.8 0.968 53.4±12.2 55.7±11.8 0.305
Sex 0.491 0.789 0.162
Male 66 (61.7) 103 (57.5) 36 (59.0) 66 (61.1) 30 (65.2) 37 (52.1)
Female 41 (38.3) 76 (42.5) 25 (41.0) 42 (38.9) 16 (34.8) 34 (47.9)
BMI (kg/m2) 23.7±3.1 23.7±3.3 0.746 24.0±3.3 24.0±3.6 0.966 23.6±2.9 23.3±2.9 0.554
Comorbidity 0.191 0.713 0.024
No 28 (26.2) 35 (19.6) 11 (18.0) 22 (20.4) 17 (37.0) 13 (18.3)
Yes 79 (73.8) 144 (80.4) 50 (82.0) 86 (79.6) 29 (63.0) 58 (81.7)
Previous abdominal surgery 0.065 0.240 0.150
No 89 (83.2) 132 (73.7) 48 (78.7) 76 (70.4) 41 (89.1) 56 (78.9)
Yes 18 (16.8) 47 (26.3) 13 (21.3) 32 (29.6) 5 (10.9) 15 (21.1)
Surgeons 0.281 0.711 0.129
A 43 (40.2) 79 (44.1) 43 (70.5) 79 (73.1) 0 0
B 42 (39.3) 76 (42.5) 18 (29.5) 29 (26.9) 24 (52.2) 47 (66.2)
C 22 (20.6) 24 (13.4) 0 0 22 (47.8) 24 (33.8)
Data are shown as mean±standard deviation or number (%).
Xi = the da Vinci Xi® system; Si = the da Vinci Si® system; BMI = body mass index.
Complications were documented in 65 (60.7%) patients in the Xi® group and 99 (55.3%) in the 
Si® group (Table 3). Most complications were grade I, which occurred in 46 (42.9%) patients 
from the Xi® group and 74 (41.34%) from the Si® group. Major complications, grade III or 
higher, occurred in 5 (4.6%) patients in the Xi® group and in 6 (3.3%) patients in the Si® group 
(Table 3). Grade III or higher complications in the Xi® group included 2 anastomosis leakages 
at the esophagojejunostomy site, a pulmonary thromboembolism, and a new-onset left bundle 
branch block. One patient in the Xi® group had anastomosis bleeding, which was controlled by 
endoscopy but complicated by cardiac arrest and death. Grade III or higher complications that 
occurred in the Si® group included a pleural effusion, a pulmonary thromboembolism, a trocar 
site herniation, a bile duct injury, and an intra-abdominal fluid collection.
The pathological analyses in Table 4 show comparable tumor size, depth of invasion, and 
histological types of tumors. The majority of patients had stage I, with 68% in the Xi® group 
and 67.4% in the Si® group. The mean number of retrieved lymph nodes was also similar, 
with 58 lymph nodes in the Xi® group and 57.4 in the Si® group.
We further divided our patients into the conventional and reduced port groups; then, we 
compared the 2 approaches using the da Vinci Xi® and the da Vinci Si® systems. In the 
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Table 2. Perioperative details
Variables All (n=286) Conventional (n=169) Reduced port (n=117)
Xi® (n=107) Si® (n=179) P-value Xi® (n=61) Si® (n=108) P-value Xi® (n=46) Si® (n=71) P-value
Operations performed 0.397 0.447 0.350
Distal gastrectomy 78 (72.9) 141 (78.8) 40 (65.6) 80 (74.1) 38 (82.6) 61 (85.9)
Total gastrectomy 21 (19.6) 23 (12.8) 13 (21.3) 15 (13.9) 8 (17.4) 8 (11.3)
Proximal gastrectomy 7 (6.5) 11 (6.1) 7 (11.5) 9 (8.3) 0 (0.0) 2 (2.8)
Completion total gastrectomy 1 (0.9) 4 (2.2) 1 (1.6) 4 (3.7) - -
Total operation time (min) 196.3±55.6 192.5±63.1 0.610 203.5±53.1 192.0±66.3 0.247 186.7±57.9 193.3±58.3 0.552
Operative preparation (min) 12.5±9.0 13.8±17.4 0.502 12.5±5.3 16.1±21.1 0.199 12.7±12.3 10.3±8.5 0.236
Docking time (min) 4.8±1.8 4.5±2.4 0.162 4.8±1.8 3.9±1.6 <0.001 4.9±1.8 5.3±3.1 0.329
Console time (min) 121.4±50.3 116.0±49.4 0.379 120.7±41.9 110.9±42.9 0.154 122.3±60.1 123.8±57.3 0.893
Specimen retrieval and closure 
(min)
53.9±28.9 54.1±32.7 0.969 60.3±25.6 55.1±36.3 0.329 45.6±31.3 52.5±26.6 0.202
Estimated blood loss (mL) 72.8±135.0 62.1±133.0 0.511 81.2±133.2 71.2±165.4 0.686 61.8±138.0 48.3±53.5 0.459
Conversion 0 (0.0) 3 (1.7) 0.178 0 (0.0) 2 (1.9) 0.285 0 (0.0) 1 (1.4) 0.419
Days to first flatus (days) 3.3±1.4 3.1±0.9 0.319 3.2±0.8 3.2±0.8 0.958 3.4±1.9 3.1±0.9 0.216
Days to sips of water (days) 2.1±1.1 2.3±0.8 0.128 2.1±0.4 2.3±0.9 0.055 2.1±1.7 2.2±0.7 0.651
Days to liquid diet (days) 3.3±2.2 3.2±0.9 0.443 3.1±0.6 3.2±0.8 0.591 3.5±3.2 3.1±0.9 0.318
Days to first soft diet (days) 4.2±2.8 4.0±2.3 0.571 3.9±0.8 4.2±2.8 0.273 4.6±4.1 3.6±1.2 0.059
Hospital length of stay (days) 7.2±11.2 6.01±3.4 0.195 7.6±14.4 6.0±3.7 0.283 6.6±4.4 5.9±2.9 0.352
Data are shown as mean±standard deviation or number (%).
Xi = the da Vinci Xi® system; Si = the da Vinci Si® system.
Table 3. Complications noted in the patients in the Xi® and Si® groups Complications
Complications All (n=286) Conventional (n=169) Reduced port (n=117)
Xi® (n=107) Si® (n=179) P-value Xi® (n=61) Si® (n=108) P-value Xi® (n=46) Si® (n=71) P-value
Presence of complications 0.187 0.142 0.761
No 39 (36.4%) 80 (44.7%) 19 (31.1%) 46 (42.6%) 20 (43.5%) 34 (47.9%)
Yes 68 (63.6%) 99 (55.3%) 42 (68.9%) 62 (57.4%) 26 (56.5%) 37 (52.1%)
Complications grade 0.269 0.039 0.751
I 49 (70.8%) 74 (74.7%) 29 (69.0%) 46 (74.2%) 20 (76.9%) 28 (80%)
II 14 (21.5%) 19 (19.2%) 10 (23.8%) 12 (19.4%) 4 (15.4%) 7 (20%)
III 2 (3.1%) 6 (6.1%) 0 (0.0%) 4 (6.5%) 2 (7.7%) 2 (5.7%)
IV 2 (3.1%) 0 (0.0%) 2 (4.8%) 0 (0.0%) - -
V 1 (1.6%) 0 (0.0%) 1 (2.3%) 0 (0.0%) - -
Values are presented as number (%).
Xi = the da Vinci Xi® system; Si = the da Vinci Si® system.
conventional group, demographic characteristics, postoperative outcomes, and pathological 
results were comparable. The Si® group had significantly shorter docking time than the Xi® 
group, 3.9 minutes and 4.8 minutes, respectively, (P<0.001).
Additionally, in the reduced port group, the Xi® and Si® groups showed similar demographic 
characteristics, as well as operative, pathological, and postoperative outcomes.
DISCUSSION
When comparing the da Vinci Xi® and da Vinci Si® systems in robotic gastrectomy for gastric 
cancer in our institution, both showed similar perioperative outcomes. We further divided 
the patients into conventional and reduced port groups, comparing the Xi® and Si® in both 
groups. The Si® group with the conventional approach had a shorter docking time than the 
Xi® group. Additionally, dividing performed procedures into distal and total gastrectomy and 
comparing the Xi® and Si® in both groups showed no significant difference, except that the 
docking time in total gastrectomy was shorter in the Si® group.
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Table 4. Pathological findings of the patients in the Xi® and Si® groups Pathology
Variables All patients (n=286) Conventional (n=169) Reduced port (n=117)
Xi® (n=107) Si® (n=179) P-value Xi® (n=61) Si® (n=108) P-value Xi® (n=46) Si® (n=71) P-value
EGC 73 (68.2) 121 (67.5) 0.828 39 (63.9) 67 (62.0) 0.806 34 (73.9) 54 (76.1) 0.774
AGC 34 (31.7) 58 (32.4) - 22 (36.1) 41 (38.0) - 12 (26.1) 17 (23.9) -
Histological type 0.973 0.346 0.817
Well differentiated 6 (5.6) 11 (6.1) 2 (3.3) 7 (6.5) 4 (8.7) 4 (5.6)
Moderately differentiated 34 (31.8) 54 (30.2) 22 (36.1) 39 (36.1) 12 (26.1) 15 (21.1)
Poorly differentiated 38 (35.5) 65 (36.3) 19 (31.1) 35 (32.4) 19 (41.3) 30 (42.3)
Mucinous 2 (1.9) 2 (1.1) 2 (3.3) 0 (0.0) 0 (0.0) 2 (2.8)
Signet ring carcinoma 24 (22.4) 39 (21.8) 15 (24.6) 22 (20.4) 9 (19.6) 17 (23.9)
Others 3 (2.8) 8 (4.5) 1 (1.6) 5 (4.6) 2 (4.3) 3 (4.2)
Tumor size (mm) 32.7±24.4 32.5±20.3 0.946 33.8±21.5 32.6±21.8 0.743 31.3±27.9 32.3±17.9 0.804
Depth of invasion 0.075 0.085 0.781
Mucosa 45 (42.1) 58 (32.4) 23 (37.7) 29 (26.9) 22 (47.8) 29 (41.4)
Submucosa 28 (26.2) 63 (35.2) 16 (26.2) 38 (35.2) 12 (26.0) 25 (34.3)
Proper muscle 11 (10.4) 15 (8.4) 7 (11.5) 8 (7.4) 4 (8.7) 7 (10.0)
Subserosal 7 (6.6) 26 (14.5) 4 (6.6) 21 (19.4) 3 (6.5) 5 (7.1)
Serosal exposure 15 (14.2) 16 (8.9) 10 (16.4) 11 (10.2) 5 (10.8) 5 (7.1)
Adjacent organ invasion* 1 (0.9) 0 (0.0) 1 (1.6) 0 (0.0) - -
No residual cancer† 0 (0.0) 1 (0.6) 0 (0.0) 1 (0.9) - -
N stage 0.721 0.415 0.449
N0 79 (73.8) 127 (70.9) 46 (75.4) 71 (65.7) 33 (71.7) 56 (78.8)
N1 21 (19.6) 38 (21.2) 11 (18) 24 (22.2) 10 (21.7) 14 (19.7)
N2 4 (3.7) 11 (6.1) 2 (3.3) 10 (9.3) 2 (4.3) 1 (1.4)
N3 3 (2.8) 3 (1.7) 2 (3.3) 3 (2.8) 1 (2.2) 0 (0.0)
Lymphovascular invasion 0.688 0.668 0.199
No 75 (70.1) 130 (72.3) 43 (70.5) 73 (67.3) 32 (69.6) 57 (80.0)
Yes 32 (29.9) 49 (27.7) 18 (29.5) 35 (32.7) 14 (30.4) 14 (20.0)
Perineural invasion 0.542 0.668 0.431
No 84 (78.5) 144 (80.4) 46 (75.4) 85 (78.7) 38 (82.6) 59 (82.9)
Yes 23 (21.4) 35 (19.6) 15 (24.6) 23 (21.3) 8 (17.4) 12 (17.1)
Retrieved LNs 58.0±23.2 57.4±24.2 0.827 60.6±24.2 59.5±26.6 0.802 54.7±21.45 54.1±19.5 0.882
Metastatic LNs 1.5±4.1 1.8±5.9 0.728 1.6±4.6 2.4±7.5 0.446 3.43±0.51 1.7±0.21 0.159
Data are shown as mean±standard deviation or number (%).
EGC = early gastric cancer; AGC = advanced gastric cancer; Xi = the da Vinci Xi® system; Si = the da Vinci Si® system; LN = lymph node.
*Invasion to distal pancreas; †Post chemotherapy after cycles of docetaxel, oxaliplatin, and S-1 regimen.
With the continuing evolution of robotic technology, new platforms must be proven to be 
safe and to have better or comparable outcomes than the previous platforms. Furthermore, 
proving that the new platforms have more benefits justifies their higher costs in comparison 
to the other platforms. Although the advances in the da Vinci Xi® system, such as facilitating 
docking and improving access, were expected to shorten the operative time in the Xi® group, 
neither total operative nor docking times were different compared to those in the Si® group 
during gastrectomy for gastric cancer. This could be because before we started using the 
da Vinci Xi® platform, a large number of procedures were performed using the da Vinci Si® 
platform. This could eventually lead to more experience with the system and, therefore, 
shorter docking time. There is an additional step of targeting the endoscope during the 
docking process using the da Vinci Xi® system, which is not required during the docking 
process of the da Vinci Si® system; therefore, the operating team must accordingly adapt. 
Moreover, the actual difference in docking time was less than 1 minute between the 2 groups, 
although it was statistically significant.
Although no similar study has been published for gastric cancer surgery comparing the da 
Vinci Xi® and da Vinci Si® platforms, previously published studies for colorectal and urology 
surgery showed similar results, with comparable outcomes. A previous study on colorectal 
surgery where a modified port placement and approach was used reported shorter total 
operative times (318±57 minutes in the Si® group vs. 285±49 minutes in the Xi® group; P<0.05) 
and docking times (23.5±2.7 minutes in the Si® group vs. 17.5±3.4 minutes in the Xi® group; 
P<0.001) in the Xi® group [11]. The study described modified trocar insertion and docking 
procedures in both groups, while we used the same approach in the Xi® and Si® groups, which 
was probably why we had similar operative times, and theirs were shortened. Another study 
comparing the da Vinci Xi® and da Vinci Si® systems during robotic nephroureterectomy also 
showed significantly shorter operative times as well as a decrease in anesthesia cost because 
of reduced duration [7]. However, other surgical outcomes were comparable in both groups. 
In our comparison study, the total operative time was slightly shorter in the Si® group, 
especially using the conventional method, but was not statistically significant.
To the best of our knowledge, this was the first study to compare the da Vinci Xi® and da 
Vinci Si® systems in the field of gastric surgery; however, there were some limitations of our 
study. We conducted this study retrospectively; therefore, there is potential for selection 
bias, although the data were extracted from our prospective database. Additionally, in our 
study, the only procedure included in the comparison was gastrectomy for gastric cancer. As 
gastrectomy is a two-quadrant surgery, the advantage of having a multi-quadrant access could 
not be fully utilized, unlike other abdominal procedures, such as colorectal surgery.
Comparisons between the da Vinci Xi® and da Vinci Si® in other different types of surgery 
requiring multi-quadrant procedures would be necessary to evaluate the advantages of 
having better anatomical access for multi-quadrant surgical procedures because of the 
overhead boom rotation without axis limitation in the da Vinci Xi® system. Another possible 
drawback was the use of the same port placement and operative approach when performing 
our procedures using both da Vinci Xi® and da Vinci Si® systems. Some modifications to take 
advantage of the features offered by the da Vinci Xi® system might produce different results. 
Furthermore, performing the same procedures on a different population may show some 
benefit because Asian patients have a relatively smaller stature, which negates the use of 
longer robotic arms for better reach.
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Our results have revealed no difference in surgical outcomes between the da Vinci Xi® and da 
Vinci Si® platforms for robotic gastrectomy. As our approach was not changed between the 2 
systems, no significant change in outcomes was shown in our results. Therefore, we cannot 
justify that the use of the da Vinci Xi® system when performing gastrectomy for gastric cancer 
improved the surgical outcomes.
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